Lipoxen Share Discussion Threads

[123asd] 09/12/2010 11:47

duplicate - most definitely. Mr Maguire stated so in recent Proactive interview. Word on other threads is that it's imminent, hence share price movement.

[aim_trader] 09/12/2010 11:46

duplicate book - a quiet board is a good thing ;)

[aim_trader] 09/12/2010 11:45

Worth watching again me thinks..
_______

Scott Maguire, CEO of Lipoxen, says it's a mystery why his company's share price is so low
Sunday, October 24, 2010
Scott Maguire, CEO of Lipoxen, tells Proactive Investors why it's a mystery that his company's share price remains so low. He points to strengthened ties with US giant Baxter International plus positive results in trials for the company's influenza and flu treatments as reasons for a bright future.

[duplicate book] 09/12/2010 11:44

Can't believe how quiet this board is!! Has everybody sold out??????????

[duplicate book] 09/12/2010 11:38

Not many selling at 14.25p either!!!!!!!!!!!!!!

[duplicate book] 09/12/2010 11:21

123asd.......is the update re the EPO Phase 11a expected by the end of this quarter?

[123asd] 09/12/2010 11:13

Yes - appointment of a Baxter director as a NED at LPX. I think that may also be tied with further co-operation agreements with Baxter or other big pharmas. But the big one is EPO Phase IIa from Serum Institute of India, our no. 2 shareholder (who's holding, incidentally, is at 30p/share). Good noises from Mr Maguire about this in recent months, so I expect it will lead to a rerating.

[duplicate book] 09/12/2010 10:56

It was a good rise again yesterday with lots of two way trading, with decent volume again. Not so much volume so far today, but mainly buying and not many people selling, even with the bid at 13.25p. If the buying continues, we will be on the up again, until we hit the next pocket of sellers. News cannot be far away now. I'm sure somebody posted on here a little while ago that there are a couple of updates due by the end of this quater?

[unconscious] 08/12/2010 19:15

I topped on the bell this morning in anticipation of news due shortly.
It's my only pharma play, but one I'm very happy to hold until we see a significant RNS and subsequent re-rating of the price.

[bobdown2] 08/12/2010 08:25

surely news must be iminent?

[bobdown2] 08/12/2010 08:18

very frisky....whats up doc? is there news in the market..

[duplicate book] 08/12/2010 08:17

Something is definitely cooking here............!!!

[bobdown2] 08/12/2010 08:04

agreed. its nice to see that its looks to be in a active mode.

[duplicate book] 08/12/2010 08:00

Marked up at the open............first few trades will show the direction we're going to go today I reckon.

[bobdown2] 08/12/2010 07:43

a pick up in volume and a rise is always nice as you do not know if it is the one that takes you upwards.

[duplicate book] 07/12/2010 21:34

Aye. We've had a few of them of late! But one morning we shall get up and that little 'A' showing on the monitor will contain news that will make our cornflakes taste so much sweeter :o))

[ohisay] 07/12/2010 21:22

Might be a false dawn !

[duplicate book] 07/12/2010 18:18

A 15% rise in the last hour on pretty good volume. News in the morning? Shall be setting my alarm clock for 6.55am and holding my breath till then :o))

[duplicate book] 07/12/2010 16:26

Heads up guys...................................!!

[duplicate book] 07/12/2010 15:49

One or two buyers returning today. Something in the air maybe? We are expecting one or two important updates before year end are we not?

[buywell2] 05/12/2010 23:29

Got to be a plus for Lipoxen

Lipoxen PLC

29 November 2010

Lipoxen plc

('Lipoxen' or the 'Company')

Collaboration partner announces Moscow ipo

Lipoxen (AIM: LPX.L), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, announces that its collaboration partner, Pharmsynthez, a leading Russian research-based pharmaceutical company, has successfully listed on the Moscow Central Stock Exchange (MICEX).

Shares in Pharmsynthez began trading on the MICEX on Thursday 25 November following an IPO which raised over 528m RUB (c. GBP10.7m), giving Pharmsynthez a market capitalisation of 1716m RUB (c. GBP34.8m) on admission. Pharmsynthez becomes only the second biotech company to be listed on the MICEX. The capital raised will assist in funding clinical development of Lipoxen licensed candidates.

Lipoxen have six projects, three PolyXen and three ImuXen candidates, currently in pre--clinical co--development with Pharmsynthez. The programme is aimed at delivering human proof of concept data in early course and Lipoxen remains hopeful that a number of the potential candidates will deliver results that justify them being advanced into the clinic.

Commenting, M. Scott Maguire, Chief Executive Officer of Lipoxen, said:

"We're delighted that our partner Pharmsynthez has successfully listed on the Moscow exchange and we offer them our warmest congratulations. The funds raised by Pharmsynthez will be used to deliver their ambitious investment programme which will accelerate their growth and enable them to introduce their unique pharmaceuticals to Russian as well as International markets.

"We have encouraging pre-clinical data on the Multiple Sclerosis vaccine candidate and we are still confident that this will be the first of the projects to reach the clinical trial stage early in 2011."

[123asd] 01/12/2010 11:52

Hybridian Small Cap Wrap:

LPX (LPX 11p / £19.50m)

AIM listed bio-pharmaceutical company specialising in the development of high-value differentiated biologicals announced this week that its collaboration partner, Pharmsynthez, a leading Russian research-based pharmaceutical company, has successfully listed on the Moscow Central Stock Exchange (MICEX) following an IPO which raised over £10.7m, giving Pharmsynthez a market capitalisation of £34.8m on admission. The capital raised will assist in funding clinical development of Lipoxen licensed candidates. Lipoxen have six projects, three PolyXen and three ImuXen candidates, currently in pre-clinical co-development with Pharmsynthez. The programme is aimed at delivering human proof of concept data in early course and Lipoxen remains hopeful that a number of the potential candidates will deliver results that justify them being advanced into the clinic. Lipoxen is hopeful that the Multiple Sclerosis vaccine candidate will be the first of the projects to reach the clinical trial stage early in 2011.
Recently Lipoxen announced that Baxter has selected a lead candidate, PSA-FVIII, a longer-acting form of Factor VIII molecule using Lipoxen's PolyXen drug delivery technology and that pre-clinical development has started. Lipoxen will receive a $2m license fee payment upfront and the issuance of a warrant to Baxter entitling them to subscribe for up to $2m in new equity in Lipoxen at an exercise price of 9.02 pence until 30 June 2015. Lipoxen's technology platform generates a large number of opportunities with each having a decent shot at returning considerable revenue streams to the company, a point that is not reflected in the current pricing of the company.

[bobdown2] 30/11/2010 15:22

its a small share in a troubled stock market.but as you point out it is a nice step forward as funds for development are not always easy to get and by having a partner in russia where there are now still only two listed biotech companies then this is probably bigger news than it first apears.

[123asd] 30/11/2010 12:27

Nobody's commented on yesterday's RNS. Minor, I know, but another piece in the picture:

Commenting, M. Scott Maguire, Chief Executive Officer of Lipoxen, said:

"We're delighted that our partner Pharmsynthez has successfully listed on the Moscow exchange and we offer them our warmest congratulations. The funds raised by Pharmsynthez will be used to deliver their ambitious investment programme which will accelerate their growth and enable them to introduce their unique pharmaceuticals to Russian as well as International markets.
"We have encouraging pre-clinical data on the Multiple Sclerosis vaccine candidate and we are still confident that this will be the first of the projects to reach the clinical trial stage early in 2011."